Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 19, 2011
Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models
Carleen Cullinane, Donna S Dorow, Susan Jackson, et al.
Dalton Transactions (Cambridge, England : 2003)
|
November 9, 2013
PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate
Brett M Paterson, Peter Roselt, Delphine Denoyer, et al.
Plos One
|
January 28, 2014
In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy
Lucy Vivash, Marie-Claude Gregoire, Viviane Bouilleret, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 17, 2013
18F-flumazenil: a γ-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy
Lucy Vivash, Marie-Claude Gregoire, Eddie W Lau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 21, 2006
A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer
Trevor Leong, Craig Everitt, Kally Yuen, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 12, 2009
In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat
Stefanie Dedeurwaerdere, Marie-Claude Gregoire, Lucy Vivash, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 8, 2017
Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of <sup>68</sup>Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer
Michael S Hofman, Peter Eu, Price Jackson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 6, 2010
Progressive metabolic and structural cerebral perturbations after traumatic brain injury: an in vivo imaging study in the rat
Ying R Liu, Lisa Cardamone, R Edward Hogan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 17, 2020
Peptide Receptor Radionuclide Therapy with <sup>67</sup>Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model
Carleen Cullinane, Charmaine M Jeffery, Peter D Roselt, et al.
Journal of the American Chemical Society
|
September 28, 2013
Diagnostic imaging agents for Alzheimer's disease: copper radiopharmaceuticals that target Aβ plaques
James L Hickey, SinChun Lim, David J Hayne, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 19, 2011
Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models
Carleen Cullinane, Donna S Dorow, Susan Jackson, et al.
Dalton Transactions (Cambridge, England : 2003)
|
November 9, 2013
PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate
Brett M Paterson, Peter Roselt, Delphine Denoyer, et al.
Plos One
|
January 28, 2014
In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy
Lucy Vivash, Marie-Claude Gregoire, Viviane Bouilleret, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 17, 2013
18F-flumazenil: a γ-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy
Lucy Vivash, Marie-Claude Gregoire, Eddie W Lau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 21, 2006
A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer
Trevor Leong, Craig Everitt, Kally Yuen, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 12, 2009
In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat
Stefanie Dedeurwaerdere, Marie-Claude Gregoire, Lucy Vivash, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 8, 2017
Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of <sup>68</sup>Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer
Michael S Hofman, Peter Eu, Price Jackson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 6, 2010
Progressive metabolic and structural cerebral perturbations after traumatic brain injury: an in vivo imaging study in the rat
Ying R Liu, Lisa Cardamone, R Edward Hogan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 17, 2020
Peptide Receptor Radionuclide Therapy with <sup>67</sup>Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model
Carleen Cullinane, Charmaine M Jeffery, Peter D Roselt, et al.
Journal of the American Chemical Society
|
September 28, 2013
Diagnostic imaging agents for Alzheimer's disease: copper radiopharmaceuticals that target Aβ plaques
James L Hickey, SinChun Lim, David J Hayne, et al.
Page
of 6